QCMA
MRKR icon

Quad Capital Management Advisors’s Marker Therapeutics MRKR Stock Holding History

Quad Capital Management Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-5,823
Closed -$298K – 47
2019
Q3 		$298K Buy
5,823
+2,698
+86% +$159K 0.15% 51
2019
Q2 		$248K Sell
3,125
-1,708
-35% -$101K 0.12% 49
2019
Q1 		$319K Buy
4,833
+2,298
+91% +$134K 0.36% 27
2018
Q4 		$141K Buy
+2,535
New +$185K 0.09% 30

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Quad Capital Management Advisors's MRKR Position: Q4 2019 in Review

Quad Capital Management Advisors sold out of Marker Therapeutics (MRKR) in Q4 2019, closing a stake of 5,823 shares — an estimated $298K sold.

Quad Capital Management Advisors first reported a position in MRKR in Q4 2018 and held it in 4 quarters. The position peaked at $319K in Q1 2019. 65 funds tracked by Wall St. Rank hold MRKR as of Q4 2019.

  • Quad Capital Management Advisors reported no remaining Marker Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Quad Capital Management Advisors sold 5,823 Marker Therapeutics shares in Q4 2019, an estimated $298K.
  • Quad Capital Management Advisors first reported a position in Marker Therapeutics in Q4 2018 and held it in 4 quarters.
  • Quad Capital Management Advisors's Marker Therapeutics position peaked at $319K in Q1 2019.
  • 65 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2019.

Based on Quad Capital Management Advisors's 13F filing for Q4 2019, filed 9 Jan 2020.